Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

What's Fueling Savient's Run?

After getting pushed to the brink by creditor Tang Capital, Savient won in court against accusations of insolvency. Shares have since bounced back to where they were pre-brouhaha. Does this make the company a buy, though? Not unless you think sales of drug Krystexxa will increase significantly, as Savient is currently cutting its way to breakeven.

Fool.com analyst David Williamson refrains from investing in biotechs that stumble out of the gate, even if happy endings do occasionally result -- for instance, in the case of Human Genome Sciences' GlaxoSmithKline(NYSE:GSK)

See more in the following video.

When it comes to a do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is another recent success story in the industry after gaining FDA approval for its innovative obesity drug. However, while the future looks bright, there are still plenty of obstacles ahead for Arena. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for all who sign up. To learn more and get started, click here now.

Author

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid